BK0689 Cosmetics Concept
- 2023.978
- +18.648+0.93%
Wakahatami (003010.SZ): Net profit in 2023 increased 60.93% year-on-year, and plans to convert 10 to 4 to 3 yuan
On April 28, Ge Longhui (003010.SZ) released its 2023 annual report. During the reporting period, the company's operating income was 1,366 billion yuan, up 12.25% year on year; net profit attributable to shareholders of listed companies was 54.295 million yuan, up 60.93% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 53.7244 million yuan, up 69.15% year on year; basic earnings per share were 0.45 yuan/share. It is proposed to distribute a cash dividend of 3 yuan (tax included) to all shareholders for every 10 shares, and a capital reserve fund will be used to transfer 4 shares to all shareholders for every 10 shares.
Marumi Co., Ltd. (603983) Comment: 1Q24 results exceeded expectations, operating improvements expected to deliver profit margins quarter by quarter
On April 26, the company announced 4Q23 revenue of 689 million yuan, +17.2% year-on-year, net profit of 85.59 million yuan, +58% year-on-year, after deducting non-net profit of 30.76 million yuan, -34% year-on-year
Jiaheng Jiahua (300955.SZ) announced its first quarter results, with a net loss of 2.91 million yuan, which changed from profit to loss over the previous year
Jiaheng Jiahua (300955.SZ) disclosed its report for the first quarter of 2024. During the reporting period, the company achieved revenue of 203 million yuan, a year-on-year decrease of 5.43%; net profit loss to mother was 2.91 million yuan, which changed from profit to loss year-on-year; after deducting loss of 2.93 million yuan in non-net profit, the year-on-year change from profit to loss. Basic earnings per share - $0.03.
Mingchen Health (002919.SZ): Net profit of 70.3647 million yuan in 2023, a year-on-year increase of 177.15%
On April 28, Ge Longhui | Mingchen Health (002919.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 1,638 billion yuan, an increase of 73.21%; net profit attributable to shareholders of listed companies was 70.3647 million yuan, up 177.15% year on year; net profit attributable to shareholders of listed companies was deducted from non-recurring profit and loss of 65.2297 million yuan to profit; basic earnings per share were 0.32 yuan/share. The company plans to distribute a cash dividend of 1.5 yuan (tax included) to all shareholders for every 10 shares, and use the capital reserve fund to transfer 2 shares for every 10 shares to all shareholders.
Express News | Shuanglu Pharmaceutical: The antiallergic drug desloratadine has submitted a marketing application and is about to be approved for marketing
Changshan Pharmaceutical (300255.SZ) announced its 2023 annual results, turning profit into loss to $1.24 billion
Changshan Pharmaceutical (300255.SZ) released its 2023 annual report. The company's revenue was 1.41 billion yuan...
Open Source Securities released a research report on April 28 stating that it gave Yuyuan Shares (600655.SH) a purchase rating. The main reasons for the rating include: 1) good sales growth in the jewelry business in the first quarter, continuing the fast
Open Source Securities released a research report on April 28 stating that it gave Yuyuan Shares (600655.SH) a purchase rating. The main reasons for the rating include: 1) good sales growth in the jewelry business in the first quarter, continuing the fast pace of exhibition stores; 2) continuous optimization and upgrading of the industry to increase the “gold content” and “new content” of various consumer industry sectors. (Mainichi Keizai Shimbun)
Express News | The State Organization Drug Joint Procurement Office reported on interviews with bidding companies for some varieties of drugs collected by the State Organization with abnormal prices
Express News | Mingchen Health: Net profit increased 31.34% year-on-year in the first quarter
Aimeike (300896): 24Q1 net profit YOY +27.38% performance in line with expectations
Incident Overview The company released its report for the first quarter of 2024. 24Q1 achieved revenue of 808 million yuan, +28.24% year over year; net profit to mother of 527 million yuan, +27.38% year over year; net profit without return to mother 5.28
Express News | Wakahatomi: Net profit of 12.8212 million yuan in the first quarter increased by 86.4% year-on-year
Jia Biyou (688089): 23-year results are in line with market expectations, 1Q24 profit margins have recovered
The 23-year results were in line with market expectations, and the 1Q24 performance slightly exceeded market expectations. The company announced 2023&1Q24 results: the company's revenue in 2023 was 404 million yuan, +2.4% year-on-year, and net profit to mother was 91 million yuan
Langzi Co., Ltd. (002612): Rapid growth in apparel and medical aesthetics, significant improvement in profitability
Core view: The company announced its 2023 financial results. According to financial reports, in 2023, the company achieved revenue of 5.145 billion yuan, +24.41% year-on-year, net profit of 225 million yuan to mother, +953.37% year-on-year, after deduction
Marumi Co., Ltd. (603983): Gross margin increased significantly in the first quarter, both brands simultaneously boosted sales growth
Core view The company's revenue in '23 was 2,226 billion yuan, +28.52%, net profit to mother was 259 million yuan, +48.93%, after deducting non-net profit of 188 million yuan, +38.16%. 24Q1 Revenue 6.
Bettany (300957) 2023 Annual Report and 2024 Quarterly Report Review: 24Q1 Revenue and Profit Achieved Double Digit Growth and Expecting Continued Improvement in Business
Event Overview: In 2023, the company achieved operating income of 5.522 billion yuan, +10.14% year on year; realized net profit of 757 million yuan, -28.02% year on year; realized net profit of 618 million yuan after deduction of non-return to mother
Minsheng Securities released a research report on April 28 stating that it gave Bethany (300957.SZ) a recommended rating. The main reasons for the rating include: 1) 2023 revenue +10.14% year-on-year, and revenue growth from offline channels is steady; 2)
Minsheng Securities released a research report on April 28 stating that it gave Bethany (300957.SZ) a recommended rating. The main reasons for the rating include: 1) 2023 revenue +10.14% year-on-year, and revenue growth from offline channels is steady; 2) gross margin decreased slightly and the cost structure is relatively stable; 3) focus on sensitive skin product development and multi-product strategy drive growth; 4) release of the 2023 equity distribution plan and the draft 2024 employee stock ownership plan. (Mainichi Keizai Shimbun)
Schierjia (301371): Online phased cost increases, proportion of cosmetics increases faster, new products can be expected
Core idea For the full year of 2023, the company achieved operating income of 1,934 billion yuan, +9.29%, after deducting non-net profit of 728 million yuan, or -5.06%. 24Q1 revenue +9.65%, net of non-net profit-5.
Marumi Co., Ltd. (603983): Revenue continues to break through, profit margins continue to be optimized
Outstanding performance in '23, profit margin increased. In '23, the company achieved revenue of 2,226 million yuan/yoy 28.52%, net profit to mother of 259 million yuan/yoy 48.93%, of which 23Q4 revenue was 6.89
21Lihe Kechuang MTN001: Resale amount of 600 million yuan
Lihe Science and Technology Innovation Group Co., Ltd. announced that the “21 Lihe Science and Technology Innovation MTN001” was resold with a resale amount of 600 million yuan, with no resale amount of 0 yuan.
Shanghai Securities released a research report on April 28 stating that it gave Shuiyang shares (300740.SZ) a purchase rating. The main reasons for the rating include: 1) “The performance was in line with expectations; the Q3 off-season company actively o
Shanghai Securities released a research report on April 28 stating that it gave Shuiyang shares (300740.SZ) a purchase rating. The main reasons for the rating include: 1) “The performance was in line with expectations; the Q3 off-season company actively optimized and upgraded the brand and paid attention to Ifidan's Double Eleven sales performance; 2) “Q2 performance exceeded expectations, and equity incentives showed confidence; 3) “23Q1 net profit also increased 25%, and the brand renewed energy to grow. (Mainichi Keizai Shimbun)